This is a preview of subscription content, log in via an institution to check access.
References
American College of Physicians. Physicians and the pharmaceutical industry. Ann of Intern Med. 1990;112:624–6.
Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians’ and patients’ attitudes toward pharmaceutical industry gifts. J Gen Intern Med. 1998;13(3):151–4.
Palmisano P, Edelstein J. Teaching drug promotion abuses to health profession students. J Med Educ. 1980;55:453–5.
Chren M, Landefeld S. Physicians’ behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271:684–9.
Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996;124:485–9.
Stelfox HT, Chua G, O’Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med. 1998;338:101–6.
Brotzman GL, Mark DH, Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;34(1):54–7.
Randall T. Ethics of receiving gifts considered. JAMA. 1991;265(4):442–3.
Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4–8.
Council on Ethical and Judicial Affairs. Code of Medical Ethics: Current Opinions with Annotations. Chicago, Ill: American Medical Association; 1997: Section 8.061.
Accreditation Council for Continuing Medical Education. Standards for Commercial Support of Continuing Medical Education, March 20, 1992.
Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students’ recall of company names or products. Acad Med. 1997;72:916–8.
Mainous AG, Hueston WJ, Rich EC. Patient perceptions of physician acceptance of gifts from the pharmaceutical industry. Arch Fam Med. 1995;4:335–9.
Blake RL, Early EK. Patients’ attitudes about gifts to physicians from pharmaceutical companies. J Am Bd Fam Pract. 1995;8:457–64.
Brotzman GL, Mark DH. The effect on resident attitudes of regulatory policies regarding pharmaceutical representative attitudes. J Gen Intern Med. 1993;8:130–4.
Hopper JA, Speece MW, Musial JL. Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med. 1997;12:639–42.
Gonzales R, Steiner J, Sande M. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 1997;278(11):901–4.
Soumerai S, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of β-blockers in elderly survivorsof acute myocardial infarction. JAMA. 1997;277(2):115–21.
Bates D, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274(1):29–34.
Beary JF. Pharmaceutical marketing has real and proven value. Characteristics of materials distributed by drug companies: four points of view. J Gen Intern Med. 1996;11:635–6.
Food and Drug Administration, U.S. Department of Health and Human Services. Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Health care Organizations or Pharmacy Benefits Management Companies. Draft Guidance, Washington, DC: U.S. Department of Health and Human Services; December 1997.
Luce BR, Lyles CA, Rentz AM. The View from Managed Care Pharmacy. Health Affairs. 1996;15:168–76.
Author information
Authors and Affiliations
Additional information
The views expressed in this article do not necessarily reflect the official positions of the Agency for Health Care Policy and Research or the U.S. Department of Health and Human Services.
Rights and permissions
About this article
Cite this article
So, A.D. Free gift. J GEN INTERN MED 13, 213–215 (1998). https://doi.org/10.1046/j.1525-1497.1998.00058.x
Issue Date:
DOI: https://doi.org/10.1046/j.1525-1497.1998.00058.x